NCT01341899View on ClinicalTrials.gov

Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2015

Conditions
Type 1 Diabetes
Interventions
PROCEDURE

immunosuppression and stem cell transplantation

Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).

Trial Locations (1)

210008

at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT01341899 - Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes | Biotech Hunter | Biotech Hunter